KRAS and neoplasm: Various laboratory-based or commercial KRAS mutation assays are used in routine practice and the majority of those have been optimized to be compatible with DNA extracted from formalin-fixed paraffin-embedded (FFPE) samples, which represent the most common form of tumor tissue specimens [17].